To address this issue, companies like Recursion are trying to identify failures early on and accelerate pre-clinical development of high potential drug candidates. While there is likely significant value just in improving the productivity of pre-clinical research, late-stage clinical failures are the primary driver of costs in today's pharmaceutical R&D model, making improving clinical success rates critical to improving the return on R&D spend. Recursion believes that the development and convergence of a r ...

Investing in growth stocks can lead to significant returns for investors in the long run. But oftentimes, the best returns come from smaller stocks, which have modest market values. These stocks can be risky options, but due to their low valuations, they tend to have the most room to rise higher if their businesses prove to be the real deal. Recursion hopes that it can help develop its own pipeline with cutting-edge technology while also helping other companies. While there isn't anything significant to sho ...

SALT LAKE CITY, June 03, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its participation in the following investor conferences: Jefferies Healthcare Conference - June 5-6, 2024 45th Annual Goldman Sachs Healthcare Conference - June 10-13, 2024 Morgan Stanley 3rd Annual Life Sciences AI Summit - June 26-27, 2024 About Recursion Recursion is a clinical stage TechBio company leading the space by decod ...

SALT LAKE CITY, May 29, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today published in Nature Genetics scientific findings that highlights a potential limitation of CRISPR-Cas9 in gene editing - a key component in understanding disease mechanisms, and developing new therapeutic approaches. Investor Contact This proximity bias, discoverable through Recursion's proprietary biological dataset, could have many down ...

SALT LAKE CITY, May 29, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today published in Nature Genetics scientific findings that highlights a potential limitation of CRISPR-Cas9 in gene editing - a key component in understanding disease mechanisms, and developing new therapeutic approaches. "Over several years, Recursion has built both unique scale and experience of working with CRISPR-Cas9. By combining the mas ...

Company Leadership Update - Robert Hershberg, MD, PhD, has been appointed as the new Chair of the Board of Recursion, effective at the end of the current term, replacing Martin Chavez who is stepping down after more than four years of leadership [1] - Dr Hershberg brings extensive experience in drug discovery and commercialization, having served on Recursion's Board since May 2020 and holding leadership roles at HilleVax, Celgene, and VentiRx Pharmaceuticals [2] - Chris Gibson, CEO and Co-founder of Recursion, expressed excitement about Dr Hershberg's appointment and gratitude for Martin Chavez's contributions to the company's growth [3] Company Overview - Recursion is a clinical-stage TechBio company that decodes biology to industrialize drug discovery, leveraging its proprietary Recursion OS platform and one of the world's largest biological and chemical datasets [4] - The company conducts millions of wet lab experiments weekly and operates one of the most powerful supercomputers in the world, combining technology, biology, and chemistry to advance medicine [4] - Recursion is headquartered in Salt Lake City and has offices in Toronto, Montréal, and the San Francisco Bay Area [5] Industry Impact - Recursion is positioned as a leader in the TechBio space, which is expected to revolutionize the biopharma industry through the intersection of scientific rigor and technology [3] - The company's approach to drug discovery, unconstrained by human bias and enabled by machine learning, represents the future of the industry [2]

SALT LAKE CITY, May 24, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced that Robert Hershberg, M.D., Ph.D, has been appointed the new Chair of the Board of Recursion, effective at the end of this term, as Martin Chavez exits after more than four years of leadership. "I'm excited to bring my clinical and scientific expertise to support Recursion's growth as Chair of the Board," said Dr. Hershberg. "I ...

These stocks are very promising, but it's important to consider the downside, too. Things aren't so bad for investors right now. We are in a bull market even though the economy is still having some problems. However, this bull run won't last forever. There will be a slowdown, equities will fall, and many won't deliver anything approaching decent returns for years after. So it's important to find stocks that can beat the market (hopefully by a large margin) over the long run. That's not easy to do, but here ...

Recursion Pharmaceuticals (RXRX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the past month, shares of this biotechnology company have returned +17.9%, compared to the Zacks S&P 500 composite's +6.1% change. During this period, the Zacks Medical - Drugs industry, which Recursion Pharmaceuticals falls in, has gained 7.1%. The key question now is: What could be the stock's futu ...

Financial Data and Key Metrics - The company ended Q1 with nearly $300 million in cash, providing a robust runway for future milestones [13] Business Line Data and Key Metrics - The company has multiple Phase 2 trial starts and readouts planned for 2024 and the next 18 months, with a roughly quarterly cadence [11] - The company has identified exciting targets in non-small cell lung cancer through its collaboration with Tempus and is integrating larger chunks of their data for broader pan-cancer causal AI models [12] - The company has sequenced its one millionth transcriptome and is leveraging this data to build a comprehensive transcriptomic map [6] Market Data and Key Metrics - The company is expanding internationally with the opening of a London office, aiming to tap into the computational biology talent pool in the UK [20][26] - The company has a strong presence in Salt Lake City, Toronto, Montreal, and San Jose, with plans for further international growth in the intermediate to long term [58][59] Company Strategy and Industry Competition - The company is focused on building a TechBio platform that integrates multiple layers of omics data, including phenomics, transcriptomics, proteomics, and enviromics, to drive drug discovery [6][43][44] - The company is leveraging active learning to optimize experimentation, achieving 80% of the information value with only 40% of the experiments [7] - The company has built a supercomputer, BioHive 2, in partnership with NVIDIA, which is one of the fastest in biopharma, enhancing its computational capabilities [9][45][46] - The company is collaborating with Roche-Genentech, Bayer, and Helix, with potential for additional partnerships in non-oncology areas like cardiovascular and metabolism [5][41][49][50] Management Commentary on Operating Environment and Future Outlook - The company believes it is uniquely positioned to lead the TechBio evolution, with a robust pipeline, platform, and team [34][39] - The company expects to demonstrate the potential of its drug discovery philosophy through a variety of catalysts in the coming quarters and years [48] - The company is moving towards autonomous discovery, where AI agents will automatically hypothesize about biology and prioritize experimentation for faster impact on patients [51] Other Important Information - The company has hired Najat Khan, a former J&J executive, as Chief R&D Officer and Chief Commercial Officer, bringing extensive experience in drug discovery and digital tools [10] - The company has announced a collaboration with Helix to access large-scale population genomics and transcriptomics data, which will be integrated with its internal data for broader disease understanding [5][42] - The company is exploring the use of organoids and steroids to improve translation and predictive ADME Tox at scale, and is working on automated synthesis to accelerate small molecule development [52] Summary of Q&A Session Question: What does success look like for upcoming Phase 2 trial readouts? - Success will be measured by meaningful biological changes that benefit patients, with next steps including aggressive pursuit of moving medicines to patients, potentially moving to Phase 3 trials or discussions about accelerated approval [14][15][16] Question: How significant is the Phase 2 readout for REC-994 in validating the platform? - The Phase 2 readout for REC-994 is a key milestone, but the company emphasizes that each program is technically uncorrelated, with successes and failures expected across the pipeline [55][56] Question: What success has been achieved with Tempus data? - The company has already identified a novel opportunity in non-small cell lung cancer using Tempus data and is refining its AI models to integrate this data with proprietary data for target identification [19][57] Question: Why is the company opening a London office? - The London office is aimed at accelerating computational biology talent acquisition, leveraging the UK's strong training in data science and biology [20][26][58] Question: How does the company view competition from Xaira? - The company welcomes competition and collaboration, believing that the primary bottleneck in TechBio is data, and that companies with high-quality datasets will make rapid progress [27][60] Question: Will the company help labs working on ultra-rare diseases like Batten disease? - The company is open to working with patient groups and labs on rare diseases, leveraging its biological maps to advance programs, though immediate solutions may not be available [21][28][61] Question: What are the next big pieces needed for faster drug discovery? - The company believes that deep, broad datasets are critical for understanding biology and accelerating drug discovery, with a focus on integrating multiple omics layers and technologies [29][62][63]